Yea, you are probably right. There is ZERO liquidity in MRV stock. The only way for a money making exit is a block buster product(s) or the sell of MRV.
MRV Communications (NASDAQ: MRVC) shares dropped 1.23% to touch a new 52-week low of $9.66. MRV Communications shares have dropped 13.45% over the past 52 weeks, while the S&P 500 index has gained 13.74% in the same period.
Noble Financial affirms Cumulus Media (Nasdaq: CMLS) at Buy with a price target of $8 following Q3 results and guidance.
Cumulus Media (CMLS) Buy Rated at Noble Financial Following Q3 Results, Outlook...
Analyst Michael Kupinski noted the following key points:
Third quarter revenues were largely in line with our estimates, which anticipated a soft advertising environment
Advertising trends appear to be improving in the fourth quarter; management indicated that core growth is pacing up with National and Local up in the double digits and in the low single digits, respectively
Despite the positive tone in core advertising in the fourth quarter, the company provided guidance that was lower than our estimate; as such, we are adjusting our estimates
Still a free cash flow story; management indicated that it plans to pare down debt by roughly $600 million over the next 18-24 months; a dollar in debt pare down should increase the equity value of the stock, or as much as $2.55 per share
Near current levels, the CMLS shares offer a compelling 21.8% free cash flow yield; we believe that the shares are compelling and timely given the prospect of an improving advertising outlook
Q414 revenue outlook moves from $341.9 million down to $333.3 million and operating cash flow from $107.3 million down to $102.0 million.
Google the headline and you will find the detail on streetinsider. Target $4 !!!
News headline came out this morning 11/19/2014
The reflection point of ICT-107 is a HUGE positive (compared to plasebo) for patients and life quality moving forward.
As of November 11, 2014:
Overland Advisors, LLC reported adding to its positions of:
Encore Capital Group Inc
Cumulus Media Inc.
BAIN CAPITAL INVESTORS LLC reported adding to its positions of:
•Quintiles Transnational Holdings Inc
•Cumulus Media Inc.
•Vonage Holdings Corp.
Maxim Maintains Buy On ImmunoCellular Following 3Q14 Update
November 14, 2014 1:31 PM EDT by Editor Jason Cohen in Exclusively Published • Healthcare
Kolbert observed, “We believe that ImmunoCeullar is smart to continue to invest in nextgeneration technologies, while at the same time pursuing the development of the company’s existing dendritic-based cell therapies. In that regard, we look forward to ICT-107 moving into a pivotal trial in 2015.” The analyst added, “We believe that ICT-107 is a viable therapy for GBM and that a pivotal trial in the US is the next step. For modeling purposes, we use a 30% discount rate in our FCFF, discounted-EPS, and sum-of-the-parts models.
In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on ImmunoCellular Therapeutics (NYSE :IMUC) with a price target of $4.00, which represents a potential upside of 560% from where the stock is currently trading. The report follows the company’s third quarter results, posting a loss of $2 million, or ($0.03) per share.